Skip to main content
OpenTrials
Completed

NCT Number: NCT04573452

Galectin-3 and Placenta Accreta

Galectins are a family of carbohydrate-binding proteins that have a high affinity to galactosides, its protein portion is located in the nucleus and the cytoplasm with its carbohydrate recognition domain which has high ability to be glycosylated inside or outside the cell.

They are expressed by vascular endothelium, immune cells (macrophages, neutrophils, and mast cells), uterus, placenta, cardiac muscle, liver, epithelium of the gastrointestinal tract, and many other tissues.

Although some galectins have intracellular functions, the majority of them have extracellular activities, which facilitate their contribution to cell adhesion, cell activation, and inflammation. Galectin-3 (Gal-3) is a unique pentamer of the galectins family and it is involved in both physiological functions; cell growth and differentiation, and pathological conditions; inflammation, fibrosis, and metastasis.

Regarding pregnancy, Gal-3 is proved to participate in angiogenesis, embryo developmental processes, and modulation of maternal immunity.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Placenta Accreta Female Urogenital Diseases and Pregnancy Complications Obstetric Labor Complications Placenta Diseases Pregnancy Complications Urogenital Diseases

Age range

20 year–40 year

Sex eligibility

Female

Study type

Observational

Primary location

Women Health Hospital - Assiut university

Asyut, 71111, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pregnant women between 28-32 weeks.
  • Age between 20-40 years.
  • Singleton pregnancy.
  • Women with suspicion of placenta accreta
  • Cases with mild vaginal bleeding or not having any vaginal bleeding.

Exclusion criteria

  • Women are known to have any medical disorders.
  • Patients with known bleeding disorders or on anticoagulant therapy.
  • Patients refuse to participate.

Treatment and study plan

Galectin-3

Diagnostic Test

Measurement of Gal-3 in Serum which will be isolated from the blood samples by ELISA (Enzyme-Linked immunosorbent Assay) (R&D Systems, Minneapolis, MN, USA).

Placental Galactin-3

Diagnostic Test

Measurement of Gal-3 in Villous and decidual tissues homogenate by ELISA

Primary outcomes

  1. Galactin 3 level in the blood

    Time frame: 6 weeks

    measured by ng/ml

Sponsors and collaborators

Lead sponsor

Assiut University

Other

Registry information

Official study title

The Role of Galectin-3 in the Pathogenesis and Prediction of Placenta Accreta

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Oct 5, 2020
Registry last updated
Oct 10, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.